TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ensysce Biosciences ( (ENSC) ) has provided an announcement.
On November 14, 2025, Ensysce Biosciences closed a $4 million convertible preferred stock financing, with the potential for an additional $16 million over the next 24 months. This funding will accelerate the Phase 3 clinical program for PF614, a flagship analgesic candidate, and support general corporate initiatives. The financing reflects strong investor confidence in Ensysce’s mission to innovate pain management solutions with built-in abuse and overdose protection.
Spark’s Take on ENSC Stock
According to Spark, TipRanks’ AI Analyst, ENSC is a Underperform.
Ensysce Biosciences faces significant financial difficulties, with severe declines in revenue and negative profitability, heavily weighing on its overall stock score. The technical analysis indicates bearish momentum, though some indicators suggest a potential for reversal. Valuation remains unattractive due to negative earnings and lack of dividends. The company must address its financial challenges to improve its stock outlook.
To see Spark’s full report on ENSC stock, click here.
More about Ensysce Biosciences
Ensysce Biosciences is a clinical stage company focused on developing novel opioids for severe pain management. The company utilizes its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to create tamper-proof analgesics that reduce the risk of drug abuse and overdose. Ensysce’s pipeline aims to offer safer pain treatment options, supported by a strong global intellectual property portfolio.
Average Trading Volume: 101,230
Technical Sentiment Signal: Sell
Current Market Cap: $6.11M
See more data about ENSC stock on TipRanks’ Stock Analysis page.